CHOP Researchers Develop Versatile and Low-Cost Technology for Targeted Long-read RNA Sequencing
Published on

CHOP researchers have developed a versatile and low-cost technology for targeted sequencing of full-length RNA molecules.
Published on
CHOP researchers have developed a versatile and low-cost technology for targeted sequencing of full-length RNA molecules.
Published on
CHOP researchers have shown that NSAIDs disrupt epithelial cells in the colon and sensitize them to C. difficile toxins by perturbing cell mitochondria.
Published on
CHOP researchers have engineered stable, universal MHC-I molecules that can be produced rapidly at scale, allowing researchers to develop vaccines and immunotherapies more quickly.
Published on
CHOP and UCLA researchers have created a tool that can discover tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.
Published on
CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.
Published on
CHOP researchers have found that Enterococcus – an antibiotic-resistant, opportunistic pathogen – works together with C. difficile, reshaping and enhancing the metabolic environment in the gut so that C. difficile can thrive.
Published on
CHOP researchers have shown that two kinases are essential in melanosome biogenesis, and that these kinases localize sequentially.
Published on
CHOP researchers have revealed the molecular mechanics of a cell-surface molecule that is a potential immunotherapy target.
Published on
CHOP researchers have developed new software called CancerVar, which helps researchers assess the clinical impacts of over 13 million somatic cancer mutations.
Published on
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.